Patient-Focused Management of Systemic Mastocytosis
The best way to manage systemic mastocytosis is to involve patients in every step of the treatment process.
dermatologists
Study Testing Cholesterol-Lowering Drug in ALGS Patients Now Recruiting
A new study testing the safety and efficacy of atorvastatin in treating xanthomas in patients with Alagille syndrome (ALGS) is recruiting participants. The prospective phase 4 study aims to clarify the safety and efficacy of atorvastatin to provide a reference for the treatment of xanthomas in children with the disease. The study will recruit 10…
Living With SM Impacts Relationships and Emotional Status Along With Physical Health
Systemic mastocytosis (SM) can have a multifaceted impact on patients’ health, relationships, and emotions, according to a study published in the European Journal of Oncology Nursing. Through purposive sampling and semistructured interviews, the study identified 3 main categories of impacts that SM had on patients’ lives—the persistent presence of the disease, struggling against ignorance, and…
Considerations for Treating Women With HAE: Lessons From a Puzzling Type 3 Case
There are a few considerations that physicians need to make when caring for female patients with HAE-C1INH type I or II or HAE-nl-C1INH.
Lanadelumab Shown to Provide Safe and Effective Prophylaxis for Hereditary Angioedema
Lanadelumab (Takhzyro®) is a safe and effective prophylactic drug for use in patients with hereditary angioedema, researchers reported in a study published in the World Allergy Organizational Journal. Hereditary angioedema with C1 inhibitor deficiency is characterized by recurring, painful edema attacks involving subcutaneous or submucosal tissue, primarily driven by the overproduction of bradykinin. The disease…
FDA Accepts New Drug Application for Potential HAE Treatment STAR-0215
The US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for STAR-0215, an experimental new treatment for hereditary angioedema (HAE). A phase 1a clinical trial of STAR-0215 in healthy volunteers is expected to begin soon, with preliminary results anticipated before the end of the year, according to a press release…
New Study Sheds Light on Proinflammatory Mechanism in Systemic Mastocytosis
Altered distribution of leukocyte subsets and a proinflammatory proteome was seen in 2 independent groups of patients with indolent systemic mastocytosis, according to a new study published in the Journal of Allergy and Clinical Immunology. This observation led the authors of the study to hypothesize that neoplastic mast cells could be recruiting and activating immune…
More Knowledge About SM May Improve Patients’ Health-Related Quality of Life
Systemic mastocytosis and mast cell activation syndrome both have a significant negative impact on patients’ health-related quality of life, a new study published in the Orphanet Journal of Rare Diseases found. However, the level of information patients receive about their disease seems to have a direct impact. “This is not only an issue in rare…
Test Your Knowledge About the Risk Factors of Hereditary Angioedema
Hereditary angioedema is a rare autosomal dominant condition. Take our quick quiz on statements about the risk factors of the disease.
New Trial Testing Lanadelumab for HAE Now Open
A new clinical trial testing the effect of lanadelumab in teenagers and adults with hereditary angioedema (HAE) is now open. The observational study will compare the rate of HAE attacks that require on-demand treatment before and within 2 years of lanadelumab treatment. The trial, sponsored by Takeda aims to recruit an estimated 50 participants at…
- Loading...
Loading...
Next post in HAE News Briefs
Loading... 
Loading...